Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$2.23 USD

2.23
26,202,260

+0.30 (15.54%)

Updated May 14, 2024 04:00 PM ET

After-Market: $2.22 -0.01 (-0.45%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy

by Zacks Equity Research

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PacBio's (PACB) New Offering to Enable High-Throughput Workflows

by Zacks Equity Research

PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Pacific Biosciences (PACB) Stock Jumps 18.7%: Will It Continue to Soar?

by Zacks Equity Research

Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

PacBio (PACB) New Revio Workflows to Boost Agricultural Output

by Zacks Equity Research

PacBio (PACB), in collaboration with Corteva Agriscience, is likely to enable groundbreaking plant and microbial long-read sequencing workflow on Revio system.

Does Pacific Biosciences (PACB) Have the Potential to Rally 30.15% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Pacific Biosciences (PACB) points to a 30.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

PacBio's (PACB) Latest Offering to Enhance Genome Analysis

by Zacks Equity Research

PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.

PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 3.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.

PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales

by Zacks Equity Research

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 8.57% and 8.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

LivaNova (LIVN) delivered earnings and revenue surprises of 1.75% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PacBio's (PACB) Latest Offering to Enhance Genome Sequencing

by Zacks Equity Research

PacBio's (PACB) latest sequencing panels are expected to simplify the study of the difficult-to-sequence or accurately map genomes, thereby aiding researchers.

PacBio's (PACB) Latest Offering to Enhance Disease Discoveries

by Zacks Equity Research

PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.

PacBio's (PACB) New Method for TR Profiling Now Available

by Zacks Equity Research

PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.

3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

Indrajit Bandyopadhyay headshot

U.S. Market Faces Worst Meltdown Since 2020: Here's Why

by Indrajit Bandyopadhyay

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag

by Zacks Equity Research

PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.

Can Pacific Biosciences (PACB) Climb 261% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.